Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

Brain ultrasound may spot danger in preeclampsia

NCT ID NCT07646561

Diagnosis Sponsor: University Tunis El Manar Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed This study
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study uses a non-invasive ultrasound called transcranial Doppler (TCD) to measure blood flow in the brains of pregnant women with preeclampsia. Researchers will compare 50 women with preeclampsia to 50 healthy pregnant women to see if TCD can detect early signs of serious complications like stroke or seizures. The goal is to find a simple, bedside tool to help doctors identify high-risk patients and improve care.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
Transcranial Doppler ultrasound
What this could lead to
If successful, this could provide a simple, bedside tool to identify which women with preeclampsia are at higher risk of serious brain complications.
What could go wrong
This is a small, observational study (100 participants) that only measures blood flow patterns. It does not test a treatment, so any benefits are limited to better risk assessment, not a cure.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Participants

100 people

The number who actually took part.

Started

Jan 2025

Finished

Jul 2025

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Who is studied

Pregnant women in their third trimester (28 weeks or more) participating in this study are divided into two groups: * Group A: Women diagnosed with preeclampsia according to standard clinical and laboratory criteria, including elevated blood pressure and proteinuria, with or without severe features. * Group B: Healthy, normotensive pregnant women without signs of preeclampsia. Participants are included after providing informed consent and are monitored for cerebral blood flow parameters using transcranial Doppler ultrasound.

Ages

18 to 45 years

Sex

Female participants only

Healthy volunteers

Accepted

You do not need to have the condition being studied to take part.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Consenting pregnant women in their third trimester (28 weeks of gestation or more) * Group A: Patients with preeclampsia, defined as: * Systolic Blood Pressure (SBP) equal to or greater than 140 mmHg and/or Diastolic Blood Pressure (DBP) equal to or greater than 90 mmHg appearing after 20 weeks of gestation with 24-hour proteinuria equal to or greater than 300 mg/24h, or * SBP equal to or greater than 140 mmHg and/or DBP equal to or greater than 90 mmHg or 24-hour proteinuria equal to or greater than 300 mg/24h with at least one of the following * Thrombocytopenia, platelets below 100,000 per cubic millimeter * Liver cytolysis, AST or ALT more than 2 times normal values * Hemolytic anemia (schistocytes present, LDH above 600) * Serum creatinine equal to or greater than 90 micromoles per liter and oliguria equal to or less than 500 milliliters per 24 hours, excluding functional or obstructive causes * Acute pulmonary edema * Subcapsular liver hematoma * Neurological or sensory signs (headache, blurred vision, tinnitus, hyperreflexia, diffuse polykinetic reflexes) * Eclampsia * Severe intrauterine growth restriction * Group B: Healthy, normotensive pregnant women * SBP less than 140 mmHg and DBP less than 90 mmHg * No clinical or biological signs of severe preeclampsia * Negative 24-hour proteinuria test, less than 300 mg/24h, if performed Exclusion Criteria: * Multiple pregnancy (twins, triplets, etc.) * History of significant neurological or cardiovascular disease * Active infection or major medical complication * Allergy or contraindication to antihypertensive therapy or magnesium sulfate * Refusal to provide informed consent

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Pre-eclampsia are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

eclampsia preeclampsia

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Pre-eclampsia

Contacts and locations

Locations

  • Tunis maternity and neonatology center, ministery of public health, Tunis ,1007

    Tunis, Tunisia

More trials for these conditions

Other studies related to the condition(s) this trial covers.